3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Radiation Injuries
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Male Urogenital Diseases
1
Lymphatic Metastasis
1
Infiltrating Bladder Urothelial Carcinoma
1
Genital Neoplasms, Male
1
Female Urogenital Diseases
1
Encopresis
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
9
pembrolizumab
7
Cisplatin
5
enfortumab vedotin
4
atezolizumab
4
Trastuzumab
4
Mitomycin
4
Carboplatin
4
Sunitinib
3
Pemetrexed
3
dodecyl maltoside
2
cabozantinib
2
Water
2
Sugammadex
2
Standard of Care
2
Saline Solution
2
Paclitaxel
2
Nivolumab
2
Neostigmine
2
Docetaxel
2
Cetuximab
2
Bevacizumab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
vinflunine
1
valrubicin
1
tucatinib
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Radiation Dose Hypofractionation
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled